The Dofigo Radium Chloride Injection label provides dosage, administration, safety, and handling information for the α‑emitting radiopharmaceutical used in…
This leaflet describes the composition, dosage, administration method, and safety precautions for the radiopharmaceutical Radium‑223 chloride (Dofigo). It is intended for use by qualified medical professionals treating castration‑resistant prostate cancer patients with symptomatic bone metastases.
Key sections include the recommended dose (55 kBq/kg), special‑population guidance, contraindications, adverse‑reaction profile, storage requirements, and disposal procedures. The document also contains pharmacological, toxicological, and clinical‑trial information supporting its therapeutic use. This manual is written in Chinese.
| Active ingredient | Radium‑223 chloride |
|---|---|
| Chemical formula | 223RaCl₂ |
Store the vials in a lead‑shielded container at temperatures below 40 °C, sealed, and do not freeze.
The most common adverse reactions (≥ 10 %) are diarrhea, nausea, vomiting, and thrombocytopenia.